Veranstaltungen

Titel und Abstract folgen.

Ansprechperson: Elisabeth Hofmeister

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Titel und Abstract folgen.

Ansprechpartner: Daehyun Kim

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Mehr Informationen folgen.

Ansprechpartnerin: Elisabeth Hofmeister

How does industrial policy affect technological change? To analyze this question, we focus on a period of unprecedented state intervention: the economic system of Nazi Germany. After 1933, the government not only tightened and introduced market restrictions, such as foreign exchange and domestic price controls, but also subsidized private investment in autarky and armament industries on a large scale. While previous research has focused on estimating aggregate investment in these industries and the extent to which private firms were forced to invest by the state, this paper analyzes the impact of these policies on R&D activities and, consequently, on technological change. To analyze the direction of technological change, we use a newly constructed patent dataset that includes a sample of over 80,200 patents filed between 1928 and 1941. We use these data to analyze three main research questions. First, did the promotion of investment in autarky industries (e.g. fuel production or ore mining) and armament industries increase patenting in the technology classes associated with these industries? Second, do we observe an increase in the importance of state-owned enterprises or military institutions for R&D? Third, do we find evidence of a change in the direction of R&D activities within large firms? 

Ansprechpartner: Michael Rose

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Medical devices are critical to the delivery of health care, but malfunctioning products can pose a threat to patients, necessitating product recalls. In addition to the direct effects of medical device recalls, such as public health protection and negative reputational and financial consequences for the recalling firm, there may be spillover effects on product development. In particular, the vacuum left by the recalled product and its reputational damage may incentivize competing firms to introduce new medical devices to the market. This study examines the impact of serious medical device recalls on subsequent new product development by competitors, as measured by new medical device submissions to the FDA. We compile data from three regulatory databases representing 11,724 new product submissions and 2,647 recalls for 7,208 unique medical device firms over a 17-year period. Using a fixed effect model and institutional features of the FDA’s clearance process, we find that serious recalls increase other firms’ new product submissions in the affected product market. We estimate that a single recall in a product market increases subsequent submissions by approximately eight percent. Moreover, we find that this relationship is attenuated in markets with more competitors. Our results indicate that firms may currently undervalue actions to avoid product recalls, and that the medical device market may be improved by regulatory efforts to enhance transparency in the recall process.

Ansprechperson: Elisabeth Hofmeister

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Firms are known to provide information to policymakers, but little is known about the conditions under which that information is used in shaping public policy. We theorize that self-interested organizations can strategically use information that is socially constructed as disinterested—scientific knowledge—to shape the language of policies. We also explore how companies’ degree of self-interest and social ties affect policymakers’ willingness to use such information. Focusing on corporate political activity in the form of voluntary filings of amicus briefs submitted to the U.S. Supreme Court, we analyze patent-related cases that the Court considered between 2000 and 2015. We find that firms that cite social science articles in their briefs are more likely to have their arguments reflected in the Court’s opinions. This relationship is positively moderated when the firm’s lawyer has prior clerkship experience at the Supreme Court, highlighting the role of social ties in tailoring briefs to the Court. However, the degree of self-interest negatively moderates the positive impact of scientific information, suggesting that credibility is compromised when firms appear overly vested in the Court ruling.  (with John P. Walsh)

Ansprechpartner: Elisabeth Hofmeister

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Recent advances in artificial intelligence (AI) technology demonstrate considerable potential to complement human capital intensive activities. While an emerging literature documents wide-ranging productivity effects of AI, relatively little attention has been paid to how AI might change the nature of work itself. How do individuals, especially those in the knowledge economy, adjust how they work when they start using AI? Using the setting of open source software, we study individual level effects that AI has on task allocation. We exploit a natural experiment arising from the deployment of GitHub Copilot, a generative AI code completion tool for software developers. Leveraging millions of work activities over a two year period, we use a program eligibility threshold to investigate the impact of AI technology on the task allocation of software developers within a quasi-experimental regression discontinuity design. We find that having access to Copilot induces such individuals to shift task allocation towards their core work of coding activities and away from non-core project management activities. We identify two underlying mechanisms driving this shift - an increase in autonomous rather than collaborative work, and an increase in exploration activities rather than exploitation. The main effects are greater for individuals with relatively lower ability. Overall, our estimates point towards a large potential for AI to transform work processes and to potentially flatten organizational hierarchies in the knowledge economy.

Ansprechpartner: Cheng Li

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

This study examines whether access to generative AI (GenAI) technologies affects entrepreneurial entry and, if so, how. We propose two mechanisms for a potential positive effect: (1) an augmentation channel that pulls prospective entrepreneurs into opportunity-driven entrepreneurship as they automate various peripheral tasks, and (2) an automation channel that pushes displaced wage workers into necessity-driven entrepreneurship as firms automate their core tasks. Leveraging the sudden release of ChatGPT, which democratized public GenAI access, we exploit industry variation in GenAI exposure for the science, technology, engineering, and mathematics (STEM) workforce in a difference-in-differences design. We find that GenAI access leads to increased incorporated entrepreneurship for individuals with higher GenAI exposure. Mechanism tests support the augmentation channel and reveal important heterogeneities in who benefits more from GenAI.
 

Ansprechpartner: Daehyun Kim

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997–2017 and add detailed information on firms’ technology dimension using patent information, next to their position in product markets. This allows us to identify the identity of targets and acquirers (who), the timing of acquisitions along the R&D process (when), and which type of R&D projects changes hands in terms of technology novelty (what). The main results can be summarized as follows. First, most of the action in M&As is in early R&D stages, still far from product markets. Second, most of the early-stage projects that change hands are high-risk/high-gain novel projects. Third, the industry leaders in the product markets are rather inactive in acquiring those novel early-stage projects. The likely acquirers of such projects are small or pipeline firms. Our results put into perspective the narrative that large incumbents acquire small targets with low-risk projects close to product launch. (joint work with J. Malek, J. Seldeslachts and R. Veugelers)

Ansprechpartnerin: Elisabeth Hofmeister

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.

Following the Covid-19 pandemic, member states of the World Health Organization (WHO) are currently negotiating a Pandemic Preparedness Agreement to prepare the world for future pandemics. The draft agreement includes a mechanism for pathogen access and benefit-sharing under Article 12, which requires users of pathogens with pandemic potential, such as vaccine manufacturers, to provide fixed percentages of vaccines, therapeutics, and diagnostics to the WHO in case of a pandemic as well as annual payments.

One key challenge in the negotiations is whether access to sequence data should be limited as an enforcement mechanism for this mechanism. However, there is no research on how de-coupled approaches to benefit-sharing, that is, approaches that do not limit access to pathogen material and data, could be used to monitor compliance. Our research investigates the sequence data disclosed in patent applications as an indicator for benefit-sharing and compliance monitoring.

Using bioinformatics tools, we identify the users of nucleotide sequences from pathogens with pandemic potential. Our preliminary data suggests that 98% of patents disclosing nucleotide sequence data from pathogens with pandemic potential relate to vaccines, therapeutics, or diagnostics.  However, these patents often include sequences from various organisms, not exclusively pathogens with pandemic potential under the WHO agreement. This indicates that this potential monitoring mechanism would also need to be harmonized with other international instruments governing access and benefit-sharing such as the Convention on Biological Diversity.

The project is part of a work stream within the NIH-funded consortium Pathogen Data Network led by the Swiss Institute of Bioinformatics and part of a work package of the European Viral Outbreak Response Alliance funded by the European Union's HORIZON program.

Ansprechpartner: Peter Slowinski

Eintragung in den Einladungsverteiler und mehr Informationen auf der Seminarseite.